![Wioleta Zelek](https://profiles-cardiff.imgix.net/attachments/2652?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Wioleta Zelek
(she/her)
- Available for postgraduate supervision
Teams and roles for Wioleta Zelek
Senior Research Fellow
Overview
I am a Group Leader at the UK Dementia Research Institute at Cardiff University and a UKRI Future Leaders Fellow. My research focuses on understanding how the complement system regulates brain health and contributes to neurodegenerative disease.
I have a strong research focus on the complement system, its biology, and its roles in disease, as well as strategies to manipulate the system for therapy. My work includes developing a toolbox of complement inhibitors, including antibodies and small molecules, that target different complement pathways and are cross-reactive with humans and rodents. To measure complement dysregulation precisely, I have developed assays and antibodies that enable accurate detection and quantification, supporting biomarker discovery and translational research.
My team combines human studies, experimental models, biomarker discovery, and therapeutic development to identify new treatments for Alzheimer's disease and other brain inflammatory diseases. A major focus of my programme is developing brain-penetrant complement therapeutics that protect synapses, reduce neuroinflammation, and slow disease progression.
https://www.raceagainstdementia.com/rad-fellows/dr-wioleta-zelek/
Publication
2026
- Arun, T. et al., 2026. Non-invasive biomarkers for neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis. Journal of Neuroimmunology 418 578969. (10.1016/j.jneuroim.2026.578969)
- Cooke, R. S. et al. 2026. Mapping of C5-blocking monoclonal antibodies reveals new C5 inhibitory epitopes and novel modes of C5 inhibition. Immunology (10.1111/imm.70180)
- Keat, S. B. K. et al. 2026. Activation of the lectin pathway drives persistent complement dysregulation in long COVID. Immunology 178 (2), pp.261-268. (10.1111/imm.70110)
- Mannes, M. , Zelek, W. M. and Trouw, L. A. 2026. Shifting from systemic to precision‐targeted complement therapies: opportunities and hurdles. European Journal of Immunology 56 (6) e70231. (10.1002/eji.70231)
- Dodd, K. C. et al., 2026. Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis. Med 7 (3) 100987. (10.1016/j.medj.2025.100987)
- Daskoulidou, N. et al., 2026. Complement in brain and eye disease: shared mechanisms, convergent pathologies, and common therapeutic opportunities. Mammalian Genome 37 (1) 33. (10.1007/s00335-026-10199-3)
2025
- Bright, M. T. et al. 2025. Complement gene expression profiles are altered in the AD frontal cortex [Abstract]. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 e100157. (10.1002/alz70855_100157)
- Nguyen, V. D. et al. 2025. Complement biosynthesis in human brain: Insights from single-nucleus transcriptomics of hippocampus.. BioRxiv (10.1101/2025.05.06.652374)
- Byrne, R. A. et al. 2025. The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans. Brain, Behavior, and Immunity 127 , pp.287-302. (10.1016/j.bbi.2025.03.026)
- Zelek, W. M. and Tenner, A. J. 2025. Complement therapeutics in neurodegenerative diseases. Immunobiology 230 (4) 153089. (10.1016/j.imbio.2025.153089)
- Li, Y. et al., 2025. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Science Advances 11 (28) eadw1731. (10.1126/sciadv.adw1731)
- Daskoulidou, N. et al. 2025. The Alzheimer's disease‐associated complement receptor 1 variant confers risk by impacting glial phagocytosis. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 (7) e70458. (10.1002/alz.70458)
- Cooke, R. S. et al. 2025. CD59, disulphide‐locked human C9 and horse C9 inhibit human membrane attack complex assembly by similar mechanisms. Immunology (10.1111/imm.70008)
- Chen, D. et al., 2025. Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI. Blood 146 (6), pp.759-764. (10.1182/blood.2024028012)
- Reed, R. M. et al., 2025. Plasma complement system markers and their association with cardiometabolic risk factors: an ethnic comparison of White European and Black African men. Endocrinology and Metabolism 328 (4), pp.e611-e619. (10.1152/ajpendo.00419.2024)
- Smith-Jackson, K. et al., 2025. The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. Kidney International 107 (4), pp.700-713. (10.1016/j.kint.2024.12.016)
- Zelek, W. M. et al. 2025. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain 148 (3), pp.941-954. (10.1093/brain/awae278)
- Zelek, W. M. et al. 2025. Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20 (S6)(10.1002/alz.090708)
2024
- Kharnaf, M. et al., 2024. Factor XII promotes the thromboinflammatory response in a rat model of veno-arterial extracorporeal membrane oxygenation.. The Journal of Thoracic and Cardiovascular Surgery 168 (2), pp.E37-E53. (10.1016/j.jtcvs.2023.08.045)
- Zelek, W. M. 2024. Is Long COVID a complement dysregulation disease?. Clinical Chemistry (10.1093/clinchem/hvae088)
- Zelek, W. M. , Bevan, R. J. and Morgan, B. P. 2024. Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia. Brain, Behavior, and Immunity 118 , pp.355-363. (10.1016/j.bbi.2024.03.017)
- Nimmo, J. et al. 2024. The complement system in neurodegenerative diseases. Clinical Science 138 (6), pp.387-412. (10.1042/cs20230513)
- Baillie, K. et al. 2024. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med 5 (3), pp.239-253. (10.1016/j.medj.2024.01.011)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Daskoulidou, N. et al. 2024. Involvement of complement in Alzheimer's Disease: From genetics through pathology to therapeutic strategies. In: Ellenbroek, B. A. et al., Current Topics in Behavioral Neurosciences. Springer, Berlin, Heidelberg. , pp.1-22. (10.1007/7854_2024_524)
2023
- Kamegai, N. et al., 2023. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical & Experimental Immunology 214 (2), pp.209-218. (10.1093/cei/uxad088)
- Veteleanu, A. et al., 2023. Alzheimer’s disease-associated complement gene variants influence plasma complement protein levels. Journal of Neuroinflammation 20 (1) 169. (10.1186/s12974-023-02850-6)
- Zelek, W. M. and Harrison, R. A. 2023. Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know. Immunobiology 228 (3) 152393. (10.1016/j.imbio.2023.152393)
- Veteleanu, A. et al. 2023. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 19 (4), pp.1383-1392. (10.1002/alz.12799)
- Goff, L. M. et al., 2023. Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity. Clinical & Experimental Immunology 212 (1)(10.1093/cei/uxad011)
- Siggins, M. K. et al., 2023. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology 168 (3), pp.473-492. (10.1111/imm.13585)
2022
- Lekova, E. et al., 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13 968206. (10.3389/fimmu.2022.968206)
- Zelek, W. M. and Morgan, B. P. 2022. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 43 (8), pp.615-628. (10.1016/j.tips.2022.02.006)
- Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10 99. (10.1186/s40478-022-01404-w)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Lewis, L. A. et al., 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225 (10), pp.1861–1864. (10.1093/infdis/jiab630)
- Kolka, C. M. et al., 2022. C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett's esophagus and esophageal adenocarcinoma. Frontiers in Immunology 13 842023. (10.3389/fimmu.2022.842023)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
2021
- Syrimi, E. et al., 2021. The immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. iScience 24 (11) 103215. (10.1016/j.isci.2021.103215)
- Zelek, W. 2021. Measuring total classical pathway and activities of individual components of the mouse complement pathway. Bio-protocol 11 (19) e4175. (10.21769/BioProtoc.4175)
- Mc Mahon, O. et al., 2021. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics 30 (13), pp.1188-1199. (10.1093/hmg/ddab086)
- Webster, J. A. et al., 2021. Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma. Cancers 13 (12) 2865. (10.3390/cancers13122865)
- Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58 (2)(10.1177/0004563220981106)
- Murrell, I. et al. 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE 16 (1) e0245382. (10.1371/journal.pone.0245382)
2020
- Buckland, M. S. et al., 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications 11 (1) 6385. (10.1038/s41467-020-19761-2)
- Zelek, W. M. and Morgan, B. P. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Frontiers in Immunology 11 (11) 612402. (10.3389/fimmu.2020.612402)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
- Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202 (9), pp.1304-1308. (10.1164/rccm.202007-2778LE)
- Zelek, W. M. et al. 2020. Characterising the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 161 (2), pp.103-113. Volume161, Issue2 October 2020 Pages 103-113. (10.1111/imm.13228)
2019
- Zelek, W. 2019. Targeting the terminal pathway in complement – driven disease.. PhD Thesis , Cardiff University.
- Zelek, W. M. et al. 2019. Compendium of current complement therapeutics. Molecular Immunology 114 , pp.341-352. (10.1016/j.molimm.2019.07.030)
- Zelek, W. M. , Taylor, P. R. and Morgan, B. P. 2019. Development and characterisation of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology 157 (4), pp.283-295. (10.1111/imm.13083)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
- Kopczynska, M. et al. 2019. Complement system biomarkers in first episode psychosis. Schizophrenia Research 204 , pp.16-22. (10.1016/j.schres.2017.12.012)
2018
- Zelek, W. M. , Harris, C. L. and Morgan, B. P. 2018. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 223 (12), pp.744-749. (10.1016/j.imbio.2018.07.016)
- Zelek, W. M. et al. 2018. Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155 (3), pp.396-403. (10.1111/imm.12982)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp.1-7. (10.1016/j.seizure.2018.05.016)
- Boshra, H. et al., 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200 (1), pp.327-335. (10.4049/jimmunol.1701238)
Articles
- Arun, T. et al., 2026. Non-invasive biomarkers for neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis. Journal of Neuroimmunology 418 578969. (10.1016/j.jneuroim.2026.578969)
- Cooke, R. S. et al. 2026. Mapping of C5-blocking monoclonal antibodies reveals new C5 inhibitory epitopes and novel modes of C5 inhibition. Immunology (10.1111/imm.70180)
- Keat, S. B. K. et al. 2026. Activation of the lectin pathway drives persistent complement dysregulation in long COVID. Immunology 178 (2), pp.261-268. (10.1111/imm.70110)
- Mannes, M. , Zelek, W. M. and Trouw, L. A. 2026. Shifting from systemic to precision‐targeted complement therapies: opportunities and hurdles. European Journal of Immunology 56 (6) e70231. (10.1002/eji.70231)
- Dodd, K. C. et al., 2026. Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis. Med 7 (3) 100987. (10.1016/j.medj.2025.100987)
- Daskoulidou, N. et al., 2026. Complement in brain and eye disease: shared mechanisms, convergent pathologies, and common therapeutic opportunities. Mammalian Genome 37 (1) 33. (10.1007/s00335-026-10199-3)
- Bright, M. T. et al. 2025. Complement gene expression profiles are altered in the AD frontal cortex [Abstract]. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 e100157. (10.1002/alz70855_100157)
- Nguyen, V. D. et al. 2025. Complement biosynthesis in human brain: Insights from single-nucleus transcriptomics of hippocampus.. BioRxiv (10.1101/2025.05.06.652374)
- Byrne, R. A. et al. 2025. The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans. Brain, Behavior, and Immunity 127 , pp.287-302. (10.1016/j.bbi.2025.03.026)
- Zelek, W. M. and Tenner, A. J. 2025. Complement therapeutics in neurodegenerative diseases. Immunobiology 230 (4) 153089. (10.1016/j.imbio.2025.153089)
- Li, Y. et al., 2025. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Science Advances 11 (28) eadw1731. (10.1126/sciadv.adw1731)
- Daskoulidou, N. et al. 2025. The Alzheimer's disease‐associated complement receptor 1 variant confers risk by impacting glial phagocytosis. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 (7) e70458. (10.1002/alz.70458)
- Cooke, R. S. et al. 2025. CD59, disulphide‐locked human C9 and horse C9 inhibit human membrane attack complex assembly by similar mechanisms. Immunology (10.1111/imm.70008)
- Chen, D. et al., 2025. Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI. Blood 146 (6), pp.759-764. (10.1182/blood.2024028012)
- Reed, R. M. et al., 2025. Plasma complement system markers and their association with cardiometabolic risk factors: an ethnic comparison of White European and Black African men. Endocrinology and Metabolism 328 (4), pp.e611-e619. (10.1152/ajpendo.00419.2024)
- Smith-Jackson, K. et al., 2025. The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. Kidney International 107 (4), pp.700-713. (10.1016/j.kint.2024.12.016)
- Zelek, W. M. et al. 2025. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain 148 (3), pp.941-954. (10.1093/brain/awae278)
- Zelek, W. M. et al. 2025. Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20 (S6)(10.1002/alz.090708)
- Kharnaf, M. et al., 2024. Factor XII promotes the thromboinflammatory response in a rat model of veno-arterial extracorporeal membrane oxygenation.. The Journal of Thoracic and Cardiovascular Surgery 168 (2), pp.E37-E53. (10.1016/j.jtcvs.2023.08.045)
- Zelek, W. M. 2024. Is Long COVID a complement dysregulation disease?. Clinical Chemistry (10.1093/clinchem/hvae088)
- Zelek, W. M. , Bevan, R. J. and Morgan, B. P. 2024. Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia. Brain, Behavior, and Immunity 118 , pp.355-363. (10.1016/j.bbi.2024.03.017)
- Nimmo, J. et al. 2024. The complement system in neurodegenerative diseases. Clinical Science 138 (6), pp.387-412. (10.1042/cs20230513)
- Baillie, K. et al. 2024. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med 5 (3), pp.239-253. (10.1016/j.medj.2024.01.011)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Kamegai, N. et al., 2023. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical & Experimental Immunology 214 (2), pp.209-218. (10.1093/cei/uxad088)
- Veteleanu, A. et al., 2023. Alzheimer’s disease-associated complement gene variants influence plasma complement protein levels. Journal of Neuroinflammation 20 (1) 169. (10.1186/s12974-023-02850-6)
- Zelek, W. M. and Harrison, R. A. 2023. Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know. Immunobiology 228 (3) 152393. (10.1016/j.imbio.2023.152393)
- Veteleanu, A. et al. 2023. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 19 (4), pp.1383-1392. (10.1002/alz.12799)
- Goff, L. M. et al., 2023. Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity. Clinical & Experimental Immunology 212 (1)(10.1093/cei/uxad011)
- Siggins, M. K. et al., 2023. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology 168 (3), pp.473-492. (10.1111/imm.13585)
- Lekova, E. et al., 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13 968206. (10.3389/fimmu.2022.968206)
- Zelek, W. M. and Morgan, B. P. 2022. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 43 (8), pp.615-628. (10.1016/j.tips.2022.02.006)
- Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10 99. (10.1186/s40478-022-01404-w)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Lewis, L. A. et al., 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225 (10), pp.1861–1864. (10.1093/infdis/jiab630)
- Kolka, C. M. et al., 2022. C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett's esophagus and esophageal adenocarcinoma. Frontiers in Immunology 13 842023. (10.3389/fimmu.2022.842023)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
- Syrimi, E. et al., 2021. The immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. iScience 24 (11) 103215. (10.1016/j.isci.2021.103215)
- Zelek, W. 2021. Measuring total classical pathway and activities of individual components of the mouse complement pathway. Bio-protocol 11 (19) e4175. (10.21769/BioProtoc.4175)
- Mc Mahon, O. et al., 2021. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics 30 (13), pp.1188-1199. (10.1093/hmg/ddab086)
- Webster, J. A. et al., 2021. Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma. Cancers 13 (12) 2865. (10.3390/cancers13122865)
- Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58 (2)(10.1177/0004563220981106)
- Murrell, I. et al. 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE 16 (1) e0245382. (10.1371/journal.pone.0245382)
- Buckland, M. S. et al., 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications 11 (1) 6385. (10.1038/s41467-020-19761-2)
- Zelek, W. M. and Morgan, B. P. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Frontiers in Immunology 11 (11) 612402. (10.3389/fimmu.2020.612402)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
- Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202 (9), pp.1304-1308. (10.1164/rccm.202007-2778LE)
- Zelek, W. M. et al. 2020. Characterising the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 161 (2), pp.103-113. Volume161, Issue2 October 2020 Pages 103-113. (10.1111/imm.13228)
- Zelek, W. M. et al. 2019. Compendium of current complement therapeutics. Molecular Immunology 114 , pp.341-352. (10.1016/j.molimm.2019.07.030)
- Zelek, W. M. , Taylor, P. R. and Morgan, B. P. 2019. Development and characterisation of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology 157 (4), pp.283-295. (10.1111/imm.13083)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
- Kopczynska, M. et al. 2019. Complement system biomarkers in first episode psychosis. Schizophrenia Research 204 , pp.16-22. (10.1016/j.schres.2017.12.012)
- Zelek, W. M. , Harris, C. L. and Morgan, B. P. 2018. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 223 (12), pp.744-749. (10.1016/j.imbio.2018.07.016)
- Zelek, W. M. et al. 2018. Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155 (3), pp.396-403. (10.1111/imm.12982)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp.1-7. (10.1016/j.seizure.2018.05.016)
- Boshra, H. et al., 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200 (1), pp.327-335. (10.4049/jimmunol.1701238)
Book sections
- Daskoulidou, N. et al. 2024. Involvement of complement in Alzheimer's Disease: From genetics through pathology to therapeutic strategies. In: Ellenbroek, B. A. et al., Current Topics in Behavioral Neurosciences. Springer, Berlin, Heidelberg. , pp.1-22. (10.1007/7854_2024_524)
Thesis
- Zelek, W. 2019. Targeting the terminal pathway in complement – driven disease.. PhD Thesis , Cardiff University.
Research
I develop brain-penetrant complement therapeutics to treat neurodegenerative diseases.
Biography
Group Leader, UK Dementia Research Institute at Cardiff University
UKRI Future Leaders Fellow, Race Against Dementia / ARUK Fellow
Leading translational research on complement therapeutics for neurodegeneration, including brain-penetrant antibodies and small molecules.
Supervisions
Current supervision
Rebekah Cooke
News articles
Contact Details
[email protected]
+44 29206 87860
Henry Wellcome Building for Biomedical Research, Floor 4th Floor, Room 4F10, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
+44 29206 87860
Henry Wellcome Building for Biomedical Research, Floor 4th Floor, Room 4F10, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
